Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications.
Dilated cardiomyopathy
Heart failure
Long-term trajectories
Loop diuretics
Prognostic associations
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
03
09
2022
accepted:
08
11
2022
pubmed:
18
11
2022
medline:
14
3
2023
entrez:
17
11
2022
Statut:
ppublish
Résumé
For patients with heart failure, prescription of loop diuretics (LD) and of higher doses are associated with an adverse prognosis. We investigated LD dose trajectories and their associations with outcomes in patients with dilated cardiomyopathy (DCM). Associations between outcomes and both furosemide-equivalent dose (FED) at enrolment and change in FED in the subsequent 24 months were evaluated. According to FED trajectory, patients were classified as (i) dose↑ (FED increase by ≥ 50% or newly initiated); (ii) dose↓ (FED decrease by ≥ 50%); (iii) stable dose (change in FED by < 50%); and (iv) never-users. The primary outcome was all-cause-death/heart transplantation/ventricular-assist-device/heart failure hospitalization. The secondary outcome was all-cause-death/heart transplantation/ventricular-assist-device. Of 1,131 patients enrolled, 738 (65%) were prescribed LD at baseline. Baseline FED was independently associated with outcome (HR per 20 mg increase: 1.12 [95% CI 1.04-1.22], p = 0.003). Of the 908 with information on FED within 24 months from enrolment, 31% were never-users; 29% were dose↓; 26% were stable dose and 14% were dose↑. In adjusted models, compared to never-users, stable dose had a higher risk of the primary outcome (HR 2.42 [95% CI 1.19-4.93], p = 0.015), while dose↑ had the worst prognosis (HR 2.76 [95% CI 1.27-6.03], p = 0.011). Results were similar for the secondary outcome. Compared to patients who remained on LD, discontinuation of LD (143, 24%) was associated with an improved outcome (HR 0.43 [95% CI 0.28-0.65], p < 0.001). In patients with DCM, LD use and increasing FED are powerful markers of adverse outcomes. Patients who never receive LD have an excellent prognosis. Among 1131 DCM patients 65% received loop diuretics at enrolment (upper left side). The bar chart on the upper right side shows the categorization in never-users/ dose↓/stable dose/ dose↑ over 24 months of follow-up. At the bottom is reported on the left side of each panel (observation period) the trajectory of LD dose in the four groups (left panel) and in patients who have their LD suspended vs those who continue LD (right panel) in the first two years. On the right side of each panel is shown the incidence of primary outcomes during the subsequent follow-up in the subgroups (outcome assessment).
Sections du résumé
BACKGROUND
BACKGROUND
For patients with heart failure, prescription of loop diuretics (LD) and of higher doses are associated with an adverse prognosis. We investigated LD dose trajectories and their associations with outcomes in patients with dilated cardiomyopathy (DCM).
METHODS
METHODS
Associations between outcomes and both furosemide-equivalent dose (FED) at enrolment and change in FED in the subsequent 24 months were evaluated. According to FED trajectory, patients were classified as (i) dose↑ (FED increase by ≥ 50% or newly initiated); (ii) dose↓ (FED decrease by ≥ 50%); (iii) stable dose (change in FED by < 50%); and (iv) never-users. The primary outcome was all-cause-death/heart transplantation/ventricular-assist-device/heart failure hospitalization. The secondary outcome was all-cause-death/heart transplantation/ventricular-assist-device.
RESULTS
RESULTS
Of 1,131 patients enrolled, 738 (65%) were prescribed LD at baseline. Baseline FED was independently associated with outcome (HR per 20 mg increase: 1.12 [95% CI 1.04-1.22], p = 0.003). Of the 908 with information on FED within 24 months from enrolment, 31% were never-users; 29% were dose↓; 26% were stable dose and 14% were dose↑. In adjusted models, compared to never-users, stable dose had a higher risk of the primary outcome (HR 2.42 [95% CI 1.19-4.93], p = 0.015), while dose↑ had the worst prognosis (HR 2.76 [95% CI 1.27-6.03], p = 0.011). Results were similar for the secondary outcome. Compared to patients who remained on LD, discontinuation of LD (143, 24%) was associated with an improved outcome (HR 0.43 [95% CI 0.28-0.65], p < 0.001).
CONCLUSIONS
CONCLUSIONS
In patients with DCM, LD use and increasing FED are powerful markers of adverse outcomes. Patients who never receive LD have an excellent prognosis. Among 1131 DCM patients 65% received loop diuretics at enrolment (upper left side). The bar chart on the upper right side shows the categorization in never-users/ dose↓/stable dose/ dose↑ over 24 months of follow-up. At the bottom is reported on the left side of each panel (observation period) the trajectory of LD dose in the four groups (left panel) and in patients who have their LD suspended vs those who continue LD (right panel) in the first two years. On the right side of each panel is shown the incidence of primary outcomes during the subsequent follow-up in the subgroups (outcome assessment).
Identifiants
pubmed: 36385396
doi: 10.1007/s00392-022-02126-8
pii: 10.1007/s00392-022-02126-8
pmc: PMC9998319
doi:
Substances chimiques
Diuretics
0
Sodium Potassium Chloride Symporter Inhibitors
0
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-430Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2022) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4–131. https://doi.org/10.1002/ejhf.2333
doi: 10.1002/ejhf.2333
pubmed: 35083827
Brunner-La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH et al (2019) Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail 7(1):13–21. https://doi.org/10.1016/j.jchf.2018.10.010
doi: 10.1016/j.jchf.2018.10.010
pubmed: 30606482
Täger T, Fröhlich H, Seiz M, Katus HA, Frankenstein L (2019) READY: relative efficacy of LDs in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials. Heart Fail Rev 24(4):461–472. https://doi.org/10.1007/s10741-019-09771-8
doi: 10.1007/s10741-019-09771-8
pubmed: 30874955
Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H et al (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 18(3):328–336. https://doi.org/10.1002/ejhf.462 (Epub 2015 Dec 23)
doi: 10.1002/ejhf.462
pubmed: 26693947
Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P et al (2016) Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther 30(6):599–609. https://doi.org/10.1007/s10557-016-6697-7
doi: 10.1007/s10557-016-6697-7
pubmed: 27819111
Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W (2017) Changes in loop diuretic dose and outcome after cardiac resynchronization therapy in patients with heart failure and reduced left ventricular ejection fractions. Am J Cardiol 120(2):267–273. https://doi.org/10.1016/j.amjcard.2017.04.021 (Epub 2017 Apr 27)
doi: 10.1016/j.amjcard.2017.04.021
pubmed: 28532770
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of the European Society of Cardiology (HFA) (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15(7):808–817. https://doi.org/10.1093/eurjhf/hft050 (Epub 2013 Mar 28)
doi: 10.1093/eurjhf/hft050
pubmed: 23537547
Kapelios CJ, Kaldara E, Ntalianis A, Nana E, Pantsios C, Repasos E et al (2014) Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: a randomized study. Int J Cardiol 177(2):690–692. https://doi.org/10.1016/j.ijcard.2014.09.156 (Epub 2014 Oct 8)
doi: 10.1016/j.ijcard.2014.09.156
pubmed: 25304067
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P et al (2019) The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155. https://doi.org/10.1002/ejhf.1369 (Epub 2019 Jan 1)
doi: 10.1002/ejhf.1369
pubmed: 30600580
Cleland JGF, Pellicori P (2021) To master heart failure, first master congestion. Lancet 398(10304):935–936. https://doi.org/10.1016/S0140-6736(21)01914-0 (Epub 2021 Aug 27)
doi: 10.1016/S0140-6736(21)01914-0
pubmed: 34461039
Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G (2018) Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 20(2):228–239. https://doi.org/10.1002/ejhf.1103 (Epub 2017 Dec 22)
doi: 10.1002/ejhf.1103
pubmed: 29271570
Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC et al (2016) Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 4(5):333–344. https://doi.org/10.1016/j.jchf.2015.11.011 (Epub 2016 Feb 10)
doi: 10.1016/j.jchf.2015.11.011
pubmed: 26874388
Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simões MV et al (2019) Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J 40(44):3605–3612. https://doi.org/10.1093/eurheartj/ehz554
doi: 10.1093/eurheartj/ehz554
pubmed: 31424503
Dauw J, Martens P, Tersalvi G, Schouteden J, Deferm S, Gruwez H, De Moor B et al (2021) Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy. Eur J Heart Fail 23(7):1110–1119. https://doi.org/10.1002/ejhf.2145
doi: 10.1002/ejhf.2145
pubmed: 33641220
Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E (2006) Sustained reverse left ventricular structural remodelling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 113(2):266–272. https://doi.org/10.1161/CIRCULATIONAHA.104.520817 (Epub 2006 Jan 9)
doi: 10.1161/CIRCULATIONAHA.104.520817
pubmed: 16401777
Merlo M, Cannatà A, Pio Loco C, Stolfo D, Barbati G, Artico J et al (2020) Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 22(7):1111–1121. https://doi.org/10.1002/ejhf.1914 (Epub 2020 Jun 26)
doi: 10.1002/ejhf.1914
pubmed: 32452075
Nuzzi V, Cannatà A, Manca P, Castrichini M, Barbati G, Aleksova A et al (2021) Atrial fibrillation in dilated cardiomyopathy: outcome prediction from an observational registry. Int J Cardiol 15(323):140–147. https://doi.org/10.1016/j.ijcard.2020.08.062 (Epub 2020 Aug 25)
doi: 10.1016/j.ijcard.2020.08.062
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M et al (2016) Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 37(23):1850–1858. https://doi.org/10.1093/eurheartj/ehv727 (Epub 2016 Jan 19)
doi: 10.1093/eurheartj/ehv727
pubmed: 26792875
Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995) Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57(6):601–609. https://doi.org/10.1016/0009-9236(95)90222-8
doi: 10.1016/0009-9236(95)90222-8
pubmed: 7781259
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
doi: 10.1016/j.echo.2014.10.003
pubmed: 25559473
Cannatà A, Merlo M, Dal Ferro M, Barbati G, Manca P, Paldino A et al (2022) Association of titin variations with late-onset dilated cardiomyopathy. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2021.5890 (Epub ahead of print)
doi: 10.1001/jamacardio.2021.5890
pmcid: 8829739
pubmed: 35138330
Manca P, Cannatà A, Nuzzi V, Bromage DI, Varrà GG, Rossi M et al (2021) Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy. Can J Cardiol 37(11):1743–1750. https://doi.org/10.1016/j.cjca.2021.06.024 (Epub 2021 Jul 14)
doi: 10.1016/j.cjca.2021.06.024
pubmed: 34273475
Manca P, Nuzzi V, Cannatà A, Merlo M, Sinagra G (2021) Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy published online ahead of print, 2021 Aug 2]. Minerva Cardiol Angiol. 10:10. https://doi.org/10.23736/S2724-5683.21.05736-7
doi: 10.23736/S2724-5683.21.05736-7
Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B et al (2021) Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail 23(7):1085–1093. https://doi.org/10.1002/ejhf.2220 (Epub 2021 Jun 28)
doi: 10.1002/ejhf.2220
pubmed: 34031968
Cleland JG, Shelton R, Nikitin N, Ford S, Frison L, Grind M (2007) Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail 9(6–7):730–739. https://doi.org/10.1016/j.ejheart.2007.01.013
doi: 10.1016/j.ejheart.2007.01.013
pubmed: 17360232
Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Díaz-Molina B et al (2020) Association between LD dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22(8):1424–1437. https://doi.org/10.1002/ejhf.1796 (Epub 2020 Apr 1)
doi: 10.1002/ejhf.1796
pubmed: 32237110
Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S et al (2019) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 393(10166):61–73. https://doi.org/10.1016/S0140-6736(18)32484-X (Epub 2018 Nov 11)
doi: 10.1016/S0140-6736(18)32484-X
pmcid: 6319251
pubmed: 30429050
Dal Ferro M, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F et al (2017) Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart 103(21):1704–1710. https://doi.org/10.1136/heartjnl-2016-311017 (Epub 2017 Apr 17)
doi: 10.1136/heartjnl-2016-311017
Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ et al (1996) Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 27(2):345–352. https://doi.org/10.1016/0735-1097(95)00464-5
doi: 10.1016/0735-1097(95)00464-5
pubmed: 8557904
Masci PG, Doulaptsis C, Bertella E, Del Torto A, Symons R, Pontone, et al (2014) Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure. Circ Heart Fail 7(3):448–456. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000996 (Epub 2014 Mar 19)
doi: 10.1161/CIRCHEARTFAILURE.113.000996
pubmed: 24647118
Pinamonti B, Di Lenarda A, Sinagra G, Camerini F (1993) Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 22(3):808–815. https://doi.org/10.1016/0735-1097(93)90195-7
doi: 10.1016/0735-1097(93)90195-7
pubmed: 8354816